Comparison · NCT01515345-1cfcf419
Standard Therapy vs Individualized Therapy: Any Bleeding Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard Therapy vs Individualized Therapy: Any Bleeding Event. Trial comparisons, record NCT01515345-1cfcf419. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01515345-1cfcf419
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0256 | 0.016 | 0.0406 | wilson | |
| Risk in group 2 | 0.0262 | 0.0139 | 0.0491 | wilson | |
| Risk difference, group 1 minus group 2 | -0.000637 | -0.0254 | 0.0188 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.976 | 0.44 | 2.17 | log | |
| Odds ratio, group 1 over group 2 | 0.975 | 0.43 | 2.21 | log | |
| Number needed to treat, for one fewer participant with the outcome on Standard Therapy than on Individualized Therapy | 1,570 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard Therapy | standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS) | 17 | 664 | OG000 |
| Group 2 | Individualized Therapy | dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer | 9 | 343 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Any Bleeding Event
- Description
Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to \< 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of \> 5 g/dL
- Time frame
- 30days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry
- NCT number
- NCT01515345
- Phases
- PHASE3
- Conditions
- Platelet Inhibition, Coronary Stent Implantation
- Interventions
- prasugrel or ticagrelor, Clopidogrel
- Lead sponsor
- Kaiser Franz Josef Hospital
- Results first posted
- 2013-05-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01515345?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01515345-1cfcf419